Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

Fig. 2

ASAS40 (a), ASDAS LDA (b), and ASDAS ID (c) responses over time. Patients initially randomized to receive placebo received open-label upadacitinib beginning at week 14. NRI-MI (NRI incorporating MI to handle missing data due to COVID-19) and AO analyses were used. AO as observed, ASAS40 ≥ 40% improvement in Assessment of SpondyloArthritis international Society response, ASDAS Ankylosing Spondylitis Disease Activity Score, CI confidence interval, ID inactive disease, LDA low disease activity, MI multiple imputation, NRI non-responder imputation, QD once daily, W week

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us